Agenus brain cancer vaccine nearly doubles survival rate in study

July 1 Tue Jul 1, 2014 7:23am EDT

July 1 (Reuters) - Agenus Inc said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.

The drug, when given in addition to standard treatment, extended median overall survival in 50 percent of newly-diagnosed glioblastoma multiforme (GBM) patients to two years in a mid-stage study.

Usually GBM patients succumb to the disease in one year. (Reporting by Natalie Grover in Bangalore; Editing by Joyjeet Das)

FILED UNDER:
A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article